Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Taysha Gene Therapies, Inc. Common Stock

TSHA

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Last trade $3.98
Day change -$0.08 (-1.97%)
Day range $3.94 – $4.12
Volume 967,812
Market cap $1.32B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.32B
Price / earnings
—
Price / book
3.71×
Price / sales
241.18×
EV / sales
172.72×
EV / EBITDA
-5.8×

Profitability

Earnings per share
-$0.48
Return on assets
-35.87%
Return on equity
-43.71%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.13×
Current ratio
18.56×
Quick ratio
18.56×
Cash ratio
18.42×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$141.66M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for TSHA, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$5.49M$0$1.99M$2.3M$2.02M
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$5.49M$0$1.99M$2.3M$2.02M
Selling, general and administrative$13.11M$12.15M$9.68M$8.83M$8.28M$8.6M$8.16M$6.63M
Research and development$28.77M$38.64M$33.81M$24.95M$25.75M$20.14M$15.57M$15.33M
Total operating expenses$41.87M$47.35M$43.49M$33.79M$34.02M$28.74M$23.72M$21.95M
Operating income-$41.87M-$47.35M-$43.49M-$28.3M-$34.02M-$26.75M-$21.42M-$19.93M
Interest expense-$4K-$6K-$9K-$12K-$15K-$17K-$19K-$22K
Income before taxes-$39.13M-$46.64M-$42.41M-$27.85M-$32.73M-$26.88M-$21.53M-$18.79M
Income taxes$0$0$0$0$0$0$0$0
Net income-$39.13M-$46.64M-$42.41M-$27.85M-$32.73M-$26.88M-$21.53M-$18.79M
Net income attributable to common shareholders-$39.13M-$46.64M-$42.41M-$27.85M-$32.73M-$26.88M-$21.53M-$18.79M
EBITDA-$41.62M-$50.49M-$43.19M-$28M-$33.74M-$26.48M-$21.14M-$19.63M
Basic earnings per share-$0.10-$0.13-$0.12-$0.08-$0.09-$0.09-$0.08-$0.07
Diluted earnings per share-$0.10-$0.13-$0.12-$0.08-$0.09-$0.09-$0.08-$0.07

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Taysha Gene Therapies priced an underwritten public offering of 32.5 million shares at $6.00 per share and pre-funded warrants, expected to raise approximately $200 million in gross proceeds. The offering is expected to close on June 26, 2026. The company is a clinical-stage biotech focused on AAV-based gene therapies for CNS diseases, with its lead program TSHA-102 in development for Rett syndrome.

GlobeNewswire Inc.

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Taysha Gene Therapies announced that on April 1, 2026, its Compensation Committee granted four new employees a total of 300,000 restricted stock units and options to purchase 92,400 shares at an exercise price of $4.31. The grants were made under the company's 2023 Inducement Plan as part of their employment agreements.

GlobeNewswire Inc.

Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update

Taysha Gene Therapies reported full-year 2025 net loss of $109.0 million and announced significant progress in its lead program TSHA-102 for Rett syndrome treatment. The company has dosed multiple patients in its REVEAL pivotal trial and received FDA clearance for the ASPIRE trial in younger patients (ages 2-4). TSHA-102 maintained a favorable safety profile with no treatment-related serious adverse events. The company expects to complete dosing in both trials by Q2 2026 and has secured FDA alignment on manufacturing and regulatory strategy for its planned BLA submission. Cash position stands at $319.8 million, sufficient to fund operations into 2028.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.